Terry Vance is the Chief Business Officer of BioMotiv, and serves on the board of Enanta Pharmaceuticals (NASDAQ: ENTA). Before joining BioMotiv, Mr. Vance founded and served as the Managing Member of EGS Healthcare Capital Partners, a venture capital fund that successfully exited four late-stage pharmaceutical companies. Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotech companies.
For fifteen years Mr. Vance was an investment banker at Salomon Brothers and Goldman Sachs, where, as head of Capital Markets for the Northeastern United States, Mr. Vance was an advisor to several pharmaceutical companies, including Merck, Warner-Lambert and American Cyanamid.
Mr. Vance holds an AB degree from Princeton University as well as an MBA degree from Stanford University. He has been a contributing editor to Diabetes Close-Up, an industry publication focused on metabolic disease, especially diabetes and obesity.